Innovative mRNA vaccine against NSCLC

Designing a platform of targeted polymeric nanoparticles
for efficient personalized therapy.

Innovative mRNA vaccine against NSCLC

Designing a platform of targeted polymeric nanoparticles
for efficient personalized therapy.

About the project

We aim to design a personalized enhanced and combined nano-immunotherapeutic approach to treat lung cancer patients, based on the use of proprietary polymeric nanoparticles encapsulating nucleic acids as active principles.

These nucleic acids will:

a) act as antigens to immunize patients against tumor antigens and achieve the self-killing of tumor cells (mRNA cancer vaccination); and

b) immunomodulate the TME by silencing key immunosuppressor genes (targeted therapy).

KNOW MORE
0
participating
countries
0
collaborating
research institutes
+0
researchers
involved
0/50
gender
balance
0M
granted

Partner
members

The project is carried out with partners from different fields, building a multidisciplinary and transversal consortium. Learn more about the members and their research profiles.

KNOW MORE

Contact

If you have questions about the project or need further information, you can leave your personal information so we can contact you.

KNOW MORE

News

MORE NEWS

The last partner is the group of Dr. Niehaus and Dr. Bednarz, from @CeBiTec @unibielefeld . They are experts on advanced imaging techniques, so they will characterize the nanoparticles biodistribution in vivo.

2

#DonesRecerca

馃煟La Dra. @CFornagueraP, professora d鈥橧QS, coordina el projecte europeu @TumorOut, que t茅 com a objectiu dissenyar una vacuna terap猫utica pel c脿ncer de pulm贸 basada en la revolucion脿ria tecnologia de vacunes de mRNA amb nanopart铆cules.

https://bit.ly/3kYdhNh

Load More